Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

24 Feb 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association. Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline and accompanying technical review have been published in Gastroenterology, the official journal of the AGA Institute.

18 Dec 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

...

23 Sep 2013

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed.

31 Aug 2013

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

13 Jun 2013

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.

13 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Crohn’s permanent stoma rates plummet in post-biologic era

Permanent stoma creation in patients with extensive Crohn’s disease has fallen to a third of its previous rate following the advent of biologic therapy, research shows.

25 Apr 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

Adalimumab News and Research

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Study: Biologic response modifying drugs can cause acute liver injury

Crohn’s permanent stoma rates plummet in post-biologic era

Bone Medical announces initial findings from BN006 proof of concept RA study

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News